Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
We describe a simple protocol using only basic lab equipment to generate and purify large quantities of a fusion protein that contains mouse Myelin Oligodendrocyte Glycoprotein. This protein can be used to induce experimental autoimmune encephalomyelitis driven by both T and B cells.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), thought to occur as a result of autoimmune responses targeting myelin. Experimental autoimmune encephalomyelitis (EAE) is the most common animal model of CNS autoimmune disease, and is typically induced via immunization with short peptides representing immunodominant CD4+ T cell epitopes of myelin proteins. However, B cells recognize unprocessed protein directly, and immunization with short peptide does not activate B cells that recognize the native protein. As recent clinical trials of B cell-depleting therapies in MS have suggested a role for B cells in driving disease in humans, there is an urgent need for animal models that incorporate B cell-recognition of autoantigen. To this end, we have generated a new fusion protein containing the extracellular domain of the mouse version of myelin oligodendrocyte glycoprotein (MOG) as well as N-terminal fusions of a His-tag for purification purposes and the thioredoxin protein to improve solubility (MOGtag). A tobacco etch virus (TEV) protease cleavage site was incorporated to allow the removal of all tag sequences, leaving only the pure MOG1-125 extracellular domain. Here, we describe a simple protocol using only standard laboratory equipment to produce large quantities of pure MOGtag or MOG1-125. This protocol consistently generates over 200 mg of MOGtag protein. Immunization with either MOGtag or MOG1-125 generates an autoimmune response that includes pathogenic B cells that recognize the native mouse MOG.
MS is a human disease characterized by chronic inflammation and neurodegeneration of the CNS which is thought to be driven by an autoimmune response directed towards myelin. The loss of myelin and axons over time result in the gradual decline of cognitive and motor function1. "Experimental Autoimmune Encephalomyelitis" is an umbrella term for animal models of autoimmune disease directed towards CNS myelin. Like human MS, EAE is typically characterized by immune cell infiltration of the CNS and, in some cases, demyelination2. However, the degree to which any given EAE model resembles human MS in part depends on the species or strain used and on the complexity of the underlying anti-myelin autoimmune response.
Anti-myelin autoimmunity can be experimentally induced in several ways, but the most common method used today is to immunize mice with a short peptide of amino acids mimicking the immunodominant CD4+ T cell epitope of a myelin protein. This represents the minimum requirement to induce a pathogenic response. Perhaps the most common of these is a 21 amino acid peptide derived from myelin oligodendrocyte glycoprotein (MOG35-55), which is used to induce EAE in C57Bl/6 mice3. However, for some experimental purposes it is desirable or even necessary to immunize with larger protein antigens and indeed there are several advantages to this over immunization with short peptide. First, because of MHC restriction, short peptides are usually only effective in a very limited range of strains, while larger protein antigens representing either the whole protein or a specific domain can be processed normally for presentation in multiple inbred mouse strains or even in different species4. Second, a larger protein antigen is capable of inducing a more complex immune response incorporating more types of lymphocytes in antigen recognition, rather than limiting antigen recognition to CD4+ T cells. For example, B cells via their B cell receptor (BCR) interact directly with whole rather than processed protein. We and others have shown that B cells activated by MOG35-55 immunization do not recognize MOG protein5. Since B cells were recently demonstrated to play a pathogenic role in human MS6, EAE models that incorporate B cells in autoimmune pathology are increasingly important.
Despite the advantages of using larger protein antigens to induce EAE, there remain few commercially available sources for such proteins. Indeed, while short peptides like MOG35-55 can be synthesized very quickly and at a relatively low cost, the commercial options for MOG protein are limited and cost substantially more to purchase. Nonetheless, there are several expression vectors available for research groups to generate MOG extracellular domain (MOG1-125) themselves. However, all of the expression systems that we have identified in the literature are based on older technologies that have since been replaced with more efficient expression systems7. Further, most are based on rat or human MOG8. For some investigations of autoimmunity in mice, an antigen based on the mouse MOG autoantigen is preferable. Finally, all MOG-based proteins that we have identified, either commercial or as expression vectors, are fusion proteins containing additional amino acids to the MOG1-125 base. These include a tag for purification and usually other sequences as well, many of which with a function we were unable to identify.
To address these limitations, we generated a novel fusion protein based on the mouse MOG extracellular domain fused to a tag containing thioredoxin to combat the known insolubility of MOG protein5. The tag sequence also contains a 6xHis sequence for purification and a TEV protease cleavage site that allows for the complete removal of all tag sequences, if desired. This is the only method that we are aware of to generate pure MOG1-125 protein. To facilitate production of large amounts of protein, the MOG1-125 sequence was codon-optimized for bacterial expression and the MOGtag fusion protein was inserted into the pET-32 expression system. Here, we describe in detail the protocol to produce and purify MOGtag protein, and pure MOG1-125, using non-specialized equipment available to most immunology laboratories.
Access restricted. Please log in or start a trial to view this content.
1. Protein Induction
NOTE: In the following steps, BL21 Escherichia coli bacteria transformed with a pET-32 vector containing the sequence for the MOGtag fusion protein (see reference5 and Figure 1) are grown to high densities and are then induced to express the MOGtag protein. See Figure 2 for overall timeline - note that days are approximate and alternate stop points are noted in the protocol. If starting with purified pET-32 MOGtag vector DNA, it will be necessary to chemically transform it into competent BL21 E. coli bacteria using ampicillin selection, as has been well-described9. Successful transformation can be confirmed by purifying DNA from selected bacteria using a standard commercial kit, followed by digestion with the restriction enzymes Age1 and Sac1 to produce a 424 bp band on an agarose gel10.
2. Harvesting MOGtag Protein
NOTE: At this stage, the bacteria will have produced large quantities of MOGtag protein. To harvest MOGtag, bacteria are first lysed in a Triton X-100 buffer followed by sonication. MOGtag is then released from inclusion bodies and denatured with imidazole and guanidine, resulting in a crude protein solution containing the MOGtag protein.
3. Protein Purification
NOTE: In the following steps the MOGtag protein will be purified through 4 rounds of absorption onto charged nickel resin (via the His-tag) and elution.
4. Measuring Protein Concentration
NOTE: Before proceeding further it is necessary to quantify the amount of purified MOGtag protein generated in section 3. This value will be used to determine the final volume to concentrate the protein to at the end of the protocol. We describe a standard Bradford Assay here. The concentration of purified MOGtag protein is determined by comparing the spectral absorbance of serially diluted MOGtag protein to a standard curve of bovine serum albumin (BSA) at a known concentration.
5. Dialysis
NOTE: Dialysis is performed to gradually remove guanidine from the solution containing purified, denatured MOGtag to allow the protein to refold. Care must be taken during this step as MOG itself is very insoluble, and while this is improved by the presence of the thioredoxin tag, it is still prone to come out of solution. Therefore, refolding should be performed gradually and at a relatively low MOGtag concentration.
6. Concentrating MOGtag Protein
NOTE: In the final step, refolded MOGtag protein is concentrated to the working dilution for storage. As MOGtag is very insoluble, it should not exceed 5 mg/ml. This concentration is approximately equimolar with 0.4 mg/ml MOG35-55 peptide, which is commonly used to induce EAE in mice (mixed 1:1 with complete Freund's adjuvant (CFA)). During the concentration process it is not uncommon for a small amount of protein to come out of solution in the form of white precipitate. Excessive precipitation is a problem, however.
7. Generating MOG1-125 from MOGtag Using TEV Protease (Optional)
NOTE: This optional step continues from the end of step 4. If MOG1-125 without any extra tag sequences is required, the tag sequences can be removed using TEV protease (Figure 4). As far as we are aware, there is no other expression system capable of generating pure MOG1-125. However, it should be noted that without the thioredoxin tag, MOG1-125 is highly insoluble and this may cause problems during purification and handling, and for this reason remove the tag if absolutely necessary for experimental reasons. Several steps are required to generate pure MOG1-125. MOGtag is first dialyzed into TEV protease cleavage buffer. Following digestion with TEV protease, the volume is reduced to aid with later purification steps, then dialyzed into buffer B, and then the His-tag containing tag sequence is removed using nickel resin. Finally, protein is quantified and pure MOG1-125 is concentrated to the final concentration.
8. SDS-PAGE Gel to Confirm MOGtag Production and Purity
NOTE: Samples taken from steps 1.4, 2.1, 3.4, and 6.4 are analyzed by standard SDS-PAGE to confirm MOGtag production and purity. This step should be performed after the final purification of either MOGtag or MOG1-125.
Access restricted. Please log in or start a trial to view this content.
Once the purification is complete, samples collected in steps 1.4, 2.1, 3.4, and the final product from step 6.4 should be run on a protein gel (Figure 3A). MOGtag should first appear as a 31.86 kDa band in the TO/N sample, but not T0, and should be the only band in the final pure product. To test whether the MOGtag protein has correctly folded, the MOGtag protein can be used to label MOG-protein specific B cells by F...
Access restricted. Please log in or start a trial to view this content.
Here, we have described a protocol for the production of MOGtag protein and how to generate pure MOG1-125 from the MOGtag protein. This protocol is based both on standard His-tag based protein purification methods, as well as a previously described protocol for the generation of an older MOG-based protein15. Although it is not described here, the primary usage of the MOGtag protein is to induce EAE through immunization with protein antigen. A protocol describing how ...
Access restricted. Please log in or start a trial to view this content.
The authors declare no competing financial interests.
This work was supported by a grant from the Multiple Sclerosis Society of Canada. RWJ is the recipient of the Waugh Family MS Society of Canada Doctoral Studentship Award.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
BL21 E. coli- pet32-MOGtag | Kerfoot lab | These bacteria are required to make the MOGtag protein. Glycerol stocks of these bacteria are available upon request. | |
LB broth miller | Bioshop | LBL407.1 | |
Ampicillin | bio basic | AB0028 | Reconsititute the powder into 50% ethanol/ 50% H2O at 100 mg/ml. Store at -20 °C. |
IPTG | Bioshop | IPT002.5 | Reconsititute the powder into H2O at 1M and store at -20 °C. |
Chicken-egg lysozyme | Bioshop | LYS702.10 | Reconstitute in H2O at 50 mg/ml and store at -80 °C. |
Triton-X100 | Sigma | T-8532 | |
Phosphate buffered saline | life technologies | 20012-027 | Commercial phosphate buffered saline is not required, any standard lab made phosphate buffered saline is sufficient. |
Sodium chloride | Bioshop | SOD004.1 | |
Tris-HCl | Bioshop | TRS002.1 | |
Imidazole | Bioshop | IMD508.100 | |
Guanidine-HCl | Sigma | G3272 | The quality must be greater than 98% purity. |
0.5 M EDTA | bioshop | EDT111.500 | |
Nickel (II) sulfate | Bioshop | NIC700.500 | |
His bind resin | EMD Millipore | 69670-3 | Store in 20% ethanol 80% H2O at 4 °C |
Anhydrous ethanol | Commercial Alcohols | P016EAAN | Dilute with water as needed. |
Glacial acetic acid | Bioshop | ACE222.1 | |
Sodium acetate trihydrate | Bioshop | SAA305.500 | |
bovine serum albumin standard | bio-rad | 500-0206 | |
Bio-rad protein assay dye reagent concentrate | bio-rad | 500-0006 | |
Ethylenediamine tetraacetic acid, disodium salt dihydrate | Fisher scientific | BP120-500 | |
Tris-base | Bioshop | TRS001.1 | |
7000 MW Snakeskin dialysis tubing | Thermoscientific | 68700 | |
2-mercaptoethanol | Sigma | M3148-25ml | This reagent should not be handled outside of a fume hood. |
AcTEV protease | lifetechnologies | 12575-015 | Producing your own TEV protease can be accomplished using (https://www.addgene.org/8827/) and purified as in reference 17 |
Polyethyleneglycol 3350 | Bioshop | PEG335.1 | |
polyethyleneglycol 8000 | Bioshop | PEG800.1 | |
Nunc MaxiSorp flat-bottom 96 well plate | ebioscience | 44-2404-21 | |
Sonicator | Fisher scientific | FB-120-110 | |
Eon microplate spectrometer | Biotek | 11-120-611 | This equipment uses the Gen5 data analysis software. |
Gen5 data analysis software | BioTek | ||
sodium dodecyl sulphate | Bioshop | SDS001 | |
bromophenol blue | Bioshop | BRO777 | |
Glycerol | Bioshop | GLY001 | |
Protein desalting columns | Thermoscientific | 89849 | |
Glycine | Bioshop | GLN001 | |
precast 12% polyacrylamide gel | bio-rad | 456-1045 | |
Rapid stain reagent | EMD Millipore | 553215 | |
Gel dock EZ imager | bio-rad | 1708270 | |
White Light Sample Tray | bio-rad | 1708272 | Used along with gel dock EZ imager for coomassie blue stains |
Protein ladder | bio-rad | 1610375 |
Access restricted. Please log in or start a trial to view this content.
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone